Twist Bioscience (TWST) – Investment Analysts’ Recent Ratings Updates

Twist Bioscience (NASDAQ: TWST) has recently received a number of price target changes and ratings updates:

• 6/15/2026 – Twist Bioscience had its price target raised by TD Cowen from $68.00 to $89.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Twist Bioscience is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $90.00 price target on the stock.
• 6/15/2026 – Twist Bioscience was given a new $89.00 price target by UBS Group AG.
• 6/15/2026 – Twist Bioscience had its price target raised by TD Cowen from $68.00 to $89.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Twist Bioscience was upgraded by Canaccord Genuity Group Inc. to “strong-buy”.
• 6/11/2026 – Twist Bioscience is now covered by Piper Sandler. They set an “overweight” rating and a $85.00 price target on the stock.
• 6/11/2026 – Twist Bioscience is now covered by Piper Sandler. They set an “overweight” rating and a $85.00 price target on the stock.
• 5/22/2026 – Twist Bioscience was given a new $80.00 price target by Leerink Partners.
• 5/5/2026 – Twist Bioscience had its price target raised by Guggenheim from $55.00 to $60.00. They now have a “buy” rating on the stock.
• 5/5/2026 – Twist Bioscience had its price target raised by Robert W. Baird from $50.00 to $65.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Twist Bioscience was upgraded by Leerink Partners from “market perform” to “outperform”. They now have a $70.00 price target on the stock.
• 5/4/2026 – Twist Bioscience had its price target raised by Barclays PLC from $55.00 to $65.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling

In related news, Director Jan Johannessen sold 12,000 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total value of $673,440.00. Following the sale, the director owned 17,754 shares of the company’s stock, valued at approximately $996,354.48. The trade was a 40.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Adam Laponis sold 4,000 shares of the business’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $60.00, for a total transaction of $240,000.00. Following the sale, the chief financial officer directly owned 118,694 shares in the company, valued at $7,121,640. The trade was a 3.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 33,170 shares of company stock worth $1,948,964 in the last three months. Insiders own 3.08% of the company’s stock.

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.